Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923067 | 1.00 | DPP4 (0.48) | DPP4DPP8LMNAHTTSMN1; SMN2 | |
| SCHEMBL4137706 | 0.76 | DPP4 (0.47) | DPP4DPP8KIT | |
| SCHEMBL3928397 | 0.73 | DPP4 (0.45) | DPP4DPP8 | |
| SCHEMBL8221016 | 0.72 | DPP4 (0.43) | DPP4DPP8KIT | |
| SCHEMBL3924048 | 0.71 | DPP4 (0.46) | DPP4DPP8PRKDC | |
| SCHEMBL3920145 | 0.70 | DPP4 (0.49) | DPP4DPP8SMN1; SMN2 | |
| SCHEMBL14820301 | 0.67 | CYP1A2 (0.40) | LMNAHTTSMN1; SMN2KITPRKDC | |
| SCHEMBL13923509 | 0.67 | DPP4 (0.71) | DPP4DPP8SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3919577 | 0.67 | DPP4 (0.70) | DPP4DPP8SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3919579 | 0.67 | DPP4 (0.70) | DPP4DPP8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | DPP4 783/4885DPP8 1978/4885LMNA 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.